FDA Approves New Drug Iqirvo for Autoimmune Liver Disease Treatment

The FDA has approved a new drug, Iqirvo (elafibranor), for treating autoimmune liver disease, specifically primary biliary cholangitis (PBC). PBC can lead to liver damage or failure if left untreated, making early detection crucial. Iqirvo offers a targeted therapeutic approach to manage PBC and prevent complications, marking a significant advancement in autoimmune liver disease treatment.